Oncology

Discovery could lead to treatments that stop cancer recurrence.

More than just biological factors can affect patient outcomes.

Top stories of the week on Specialty Pharmacy Times.

Expansion covers patients who have greater than 30% myeloblasts.

Average time for withdrawals in colonoscopies came in at approximately 8.6 minutes.

Intralesional interleukin-2 shows promise in cutaneous melanoma metastases.

Technology may help improve patient outcomes through enhanced personalized medicine.

Nanopore technology may soon be adapted for early disease detection.

Bristol-Myers Squibb will take part in Leerink Partners Immuno-Oncology Roundtable on October 1.

Findings could eliminate need for weeks of treatments that carry severe side effects.

Research may help tailor treatments to individual patients.

Average reimbursement for Part B oncology drugs is 52% higher in 340B hospitals than in community cancer clinics.

Treatment seeks to reverse chemotherapy resistance caused by P-glycoprotein.

Chronic lymphocytic leukemia treatment reprograms T cells to hunt and kill cancer cells.

Newly discovered epigenetic markers offer hope.

Study reveals targets on the tumor cell that can be recognized by killer T-cells.

Top recent developments in cancer research.

Lymphoma and lung cancer present significant risk to RA patients.

Research will lead to novel viral and immunologic treatments.

Combination of immunotherapy and aspirin showed a substantial decrease in bowel and melanoma skin cancer growth in mice.

Genetic variants regulate immune cells with important roles in immunodeficiency disorders.

Treatment removes a tumor's defenses.

Chemotherapy drugs can convert gastrointestinal bacteria into toxic species that causes severe diarrhea.

Acupuncture found to help patients manage debilitating side effects from breast cancer treatment.

Researchers seek to improve care for rare, difficult-to-treat, and aggressive cancers.

Adoptive cell transfer procedure involves extracting and growing immune cells outside of the body.

Anticancer medication response strongly linked to genetic ancestry.

Engineered chimeric antigen receptor T-cells differentiate between cancerous and normal cells.

Concerns raised over treatment that fights fungal infections in lung transplant patients.

Research may lead to new combination therapies that attack different parts of cancer cells.